JP2019511548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511548A5 JP2019511548A5 JP2018554080A JP2018554080A JP2019511548A5 JP 2019511548 A5 JP2019511548 A5 JP 2019511548A5 JP 2018554080 A JP2018554080 A JP 2018554080A JP 2018554080 A JP2018554080 A JP 2018554080A JP 2019511548 A5 JP2019511548 A5 JP 2019511548A5
- Authority
- JP
- Japan
- Prior art keywords
- fluoro
- hydrogen
- compound according
- disorders
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 9
- 230000000926 neurological effect Effects 0.000 claims description 4
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 claims description 3
- -1 chloro, cyano, methyl Chemical group 0.000 claims description 3
- 208000030990 Impulse-control disease Diseases 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 125000001153 fluoro group Chemical group F* 0.000 claims 11
- 150000002431 hydrogen Chemical class 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 125000001309 chloro group Chemical group Cl* 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 11
- 208000022821 personality disease Diseases 0.000 description 9
- 208000019454 Feeding and Eating disease Diseases 0.000 description 6
- 230000005032 impulse control Effects 0.000 description 6
- 208000011117 substance-related disease Diseases 0.000 description 6
- 206010012289 Dementia Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 201000000980 schizophrenia Diseases 0.000 description 5
- 208000024827 Alzheimer disease Diseases 0.000 description 4
- 206010006550 Bulimia nervosa Diseases 0.000 description 4
- 206010012335 Dependence Diseases 0.000 description 4
- 208000030814 Eating disease Diseases 0.000 description 4
- 208000012902 Nervous system disease Diseases 0.000 description 4
- 208000025966 Neurological disease Diseases 0.000 description 4
- 102100028141 Orexin/Hypocretin receptor type 1 Human genes 0.000 description 4
- 208000030963 borderline personality disease Diseases 0.000 description 4
- 235000014632 disordered eating Nutrition 0.000 description 4
- 208000020016 psychiatric disease Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 description 3
- 229940123730 Orexin receptor antagonist Drugs 0.000 description 3
- 102100037588 Orexin receptor type 2 Human genes 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- RHLMXWCISNJNDH-UHFFFAOYSA-N n-[2-[3-[[5-[3-(dimethylcarbamoyl)phenyl]-2-methoxyphenyl]sulfonylamino]anilino]ethyl]-3-methylbenzamide Chemical compound COC1=CC=C(C=2C=C(C=CC=2)C(=O)N(C)C)C=C1S(=O)(=O)NC(C=1)=CC=CC=1NCCNC(=O)C1=CC=CC(C)=C1 RHLMXWCISNJNDH-UHFFFAOYSA-N 0.000 description 3
- 208000015238 neurotic disease Diseases 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 208000019116 sleep disease Diseases 0.000 description 3
- 201000009032 substance abuse Diseases 0.000 description 3
- 231100000736 substance abuse Toxicity 0.000 description 3
- 208000027559 Appetite disease Diseases 0.000 description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 208000019022 Mood disease Diseases 0.000 description 2
- 206010029333 Neurosis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000025371 Taste disease Diseases 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 description 2
- 208000015891 sexual disease Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 235000019669 taste disorders Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- VWMQXAYLHOSRKA-UHFFFAOYSA-N 5-chloro-1,3-benzoxazole Chemical compound ClC1=CC=C2OC=NC2=C1 VWMQXAYLHOSRKA-UHFFFAOYSA-N 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 206010067948 Compulsive shopping Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010013142 Disinhibition Diseases 0.000 description 1
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 208000001836 Firesetting Behavior Diseases 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 208000001456 Jet Lag Syndrome Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 208000027089 Parkinsonian disease Diseases 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 206010034158 Pathological gambling Diseases 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000036623 Severe mental retardation Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 208000028505 alcohol-related disease Diseases 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 208000022804 avoidant personality disease Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000015046 intermittent explosive disease Diseases 0.000 description 1
- 208000033915 jet lag type circadian rhythm sleep disease Diseases 0.000 description 1
- 206010023461 kleptomania Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- CKJNUZNMWOVDFN-UHFFFAOYSA-N methanone Chemical compound O=[CH-] CKJNUZNMWOVDFN-UHFFFAOYSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000036473 myasthenia Effects 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 235000020825 overweight Nutrition 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000003368 psychostimulant agent Substances 0.000 description 1
- 201000004645 pyromania Diseases 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- JYTNQNCOQXFQPK-MRXNPFEDSA-N suvorexant Chemical compound C([C@H]1C)CN(C=2OC3=CC=C(Cl)C=C3N=2)CCN1C(=O)C1=CC(C)=CC=C1N1N=CC=N1 JYTNQNCOQXFQPK-MRXNPFEDSA-N 0.000 description 1
- 229960001198 suvorexant Drugs 0.000 description 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 1
- 208000016686 tic disease Diseases 0.000 description 1
- 208000002271 trichotillomania Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16165529.5 | 2016-04-15 | ||
| EP16165529 | 2016-04-15 | ||
| PCT/EP2017/058315 WO2017178340A1 (en) | 2016-04-15 | 2017-04-07 | Novel n-[(pyridyloxy)propanyl]benzamides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511548A JP2019511548A (ja) | 2019-04-25 |
| JP2019511548A5 true JP2019511548A5 (enExample) | 2021-05-20 |
| JP6918827B2 JP6918827B2 (ja) | 2021-08-11 |
Family
ID=55755463
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554080A Active JP6918827B2 (ja) | 2016-04-15 | 2017-04-07 | 新規なｎ−［（ピリジルオキシ）プロパニル］ベンズアミド |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US10787432B2 (enExample) |
| EP (1) | EP3442958B1 (enExample) |
| JP (1) | JP6918827B2 (enExample) |
| WO (1) | WO2017178340A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10738031B2 (en) | 2016-04-15 | 2020-08-11 | Boehringer Ingelheim International Gmbh | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity |
| EP3442963B1 (en) * | 2016-04-15 | 2020-05-06 | Boehringer Ingelheim International GmbH | N-[(pyrazinyloxy)propanyl]benzamides |
| JP6591698B2 (ja) * | 2016-04-15 | 2019-10-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なｎ−［（ピリミジニルアミノ）プロパニル］−およびｎ−［（ピラジニルアミノ）プロパニル］アリールカルボキサミド |
| US10710984B2 (en) | 2016-04-15 | 2020-07-14 | Boehringer Ingelheim International Gmbh | N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides |
| EP3442967B1 (en) | 2016-04-15 | 2020-05-13 | Boehringer Ingelheim International GmbH | Novel n-[(pyrimidinyloxy)propanyl]benzamides |
| JP6918827B2 (ja) | 2016-04-15 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なｎ−［（ピリジルオキシ）プロパニル］ベンズアミド |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130341D0 (en) * | 2001-12-19 | 2002-02-06 | Smithkline Beecham Plc | Compounds |
| WO2009011775A1 (en) | 2007-07-13 | 2009-01-22 | Merck & Co., Inc. | Amidoethyl alkylamino orexin receptor antagonists |
| HK1203197A1 (en) * | 2012-06-15 | 2015-10-23 | Taisho Pharmaceutical Co., Ltd. | Branched chain alkyl heteroaromatic ring derivative |
| JP2016028017A (ja) | 2012-12-13 | 2016-02-25 | 大正製薬株式会社 | フッ素置換ピペリジン化合物 |
| JP2017100950A (ja) | 2014-04-04 | 2017-06-08 | 大正製薬株式会社 | オキソ複素環誘導体 |
| GB201415569D0 (en) * | 2014-09-03 | 2014-10-15 | C4X Discovery Ltd | Therapeutic Compounds |
| US10738031B2 (en) * | 2016-04-15 | 2020-08-11 | Boehringer Ingelheim International Gmbh | N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity |
| EP3442963B1 (en) * | 2016-04-15 | 2020-05-06 | Boehringer Ingelheim International GmbH | N-[(pyrazinyloxy)propanyl]benzamides |
| JP6591698B2 (ja) * | 2016-04-15 | 2019-10-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なｎ−［（ピリミジニルアミノ）プロパニル］−およびｎ−［（ピラジニルアミノ）プロパニル］アリールカルボキサミド |
| US10710984B2 (en) | 2016-04-15 | 2020-07-14 | Boehringer Ingelheim International Gmbh | N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides |
| EP3442967B1 (en) | 2016-04-15 | 2020-05-13 | Boehringer Ingelheim International GmbH | Novel n-[(pyrimidinyloxy)propanyl]benzamides |
| JP6918827B2 (ja) | 2016-04-15 | 2021-08-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規なｎ−［（ピリジルオキシ）プロパニル］ベンズアミド |
-
2017
- 2017-04-07 JP JP2018554080A patent/JP6918827B2/ja active Active
- 2017-04-07 US US16/090,343 patent/US10787432B2/en active Active
- 2017-04-07 EP EP17715182.6A patent/EP3442958B1/en active Active
- 2017-04-07 WO PCT/EP2017/058315 patent/WO2017178340A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3166936A1 (en) | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders | |
| JP2026048894A (ja) | ５－メトキシ－ｎ，ｎ－ジメチルトリプタミンの安息香酸塩を含む組成物 | |
| RU2007139255A (ru) | Новые оксадиазольные производные и их медицинское применение | |
| JP5525500B2 (ja) | １ｈ−キナゾリン−２，４−ジオンおよびａｍｐａ受容体リガンドとしてのそれらの使用 | |
| CN109963854A (zh) | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2008534627A5 (enExample) | ||
| TWI224102B (en) | Serotonergic agents | |
| JP6421185B2 (ja) | ベンゾイミダゾール−プロリン誘導体の使用 | |
| JP2015506382A5 (enExample) | ||
| JP2013526544A5 (enExample) | ||
| JP6987384B2 (ja) | ベンゾジアゼピン誘導体、組成物、および認知障害を処置するための方法 | |
| RU2010126622A (ru) | Конденсированные с арилом и гетероарилом имидазо[1, 5-а]пиразины в качестве ингибиторов фосфодиэстеразы 10 | |
| JP2009538867A5 (enExample) | ||
| CN110366555A (zh) | 甾族类衍生物调节剂、其制备方法和应用 | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| JP2021528427A (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
| JP2015521642A5 (enExample) | ||
| JP7167236B2 (ja) | せん妄の予防または治療剤 | |
| JP2017536409A5 (enExample) | ||
| JP5744203B2 (ja) | オレキシン受容体拮抗薬としてのプロリンスルフォンアミド誘導体 | |
| US7723324B2 (en) | Imidazo[1,2-A]pyridine anxiolytics | |
| AU2022399234A1 (en) | Analogues of mdma for modulating sert, dat, and / or net activity | |
| JP2015521643A5 (enExample) | ||
| JP2009502914A5 (enExample) | ||
| TW201446243A (zh) | 4-(5-(4-氯苯基)-2-(2-環丙基乙醯基)-1,4-二甲基-1氫-吡咯-3-基)苯磺醯胺作為α7尼古丁乙醯膽鹼受體調節劑 |